Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April

Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 32,605,480 cases with around 580,060 deaths. India confirmed a total of at least 21,491,590 cases and 234,080 deaths, while Brazil reported over 15,003,560 COVID-19 cases with 416,940 deaths. In total, there were at least 156,151,460 cases of COVID-19 worldwide with more than 3,258,410 deaths, according to data compiled by Johns Hopkins University.


Leading and Lagging Sectors


Health care shares rose 1.2% on Friday. Meanwhile, top gainers in the sector included iBio, Inc. IBIO, up 19%, and Epizyme, Inc. EPZM, up 21%.


In trading on Friday, financial shares fell 0.2%.


Top Headline

The Bureau of Labor Statistics released employment data for the month of April.

The nonfarm payroll number came in at +266,000, well worse than consensus economist expectations of +1 million. The unemployment rate increased by 0.1% to 6.1%. April’s job growth represents a sharp drop from the 770,000 jobs the economy gained in March.

 

Equities Trading UP


InnSuites Hospitality Trust IHT shares shot up 86% to $4.53.


Shares of Regional Health Properties, Inc. RHE got a boost, shooting 47% to $21.95 after dropping 23% on Thursday.


LM Funding America, Inc. LMFA shares were also up, gaining 51% to $5.72. The company announced a 1-for-5 reverse stock split effective May 7.

Check out these big movers of the day


Equities Trading DOWN

ChemoCentryx, Inc. CCXI shares tumbled 61% to $10.79 after the company said the FDA's Arthritis Advisory Committee that evaluated avacopan for the treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis gave a split verdict on whether the efficacy data support approval of avacopan. The committee voted 9-7 in favor of safety and 10-8 that the benefit-risk profile is adequate to support approval of avacopan at the proposed dose of 30 mg twice daily.

Shares of Centerra Gold Inc. CGAU were down 31% to $6.85.

Orphazyme A/S ORPH was down, falling 28% to $6.12 after the company announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints.


Commodities


In commodity news, oil traded up 0.2% to $64.85, while gold traded up 0.2% to $1,820.00.


Silver traded down 0.1% Friday to $27.465 while copper rose 2.5% to $4.7185.


Euro zone

European shares were higher today. The eurozone’s STOXX 600 climbed 0.7%, the Spanish Ibex Index rose 0.6% and the German DAX 30 gained 1.3%. Meanwhile, the London’s FTSE 100 gained 0.8%, French CAC 40 rose 0.3% and Italy’s FTSE MIB gained 0.2%.

UK’s construction PMI slipped to 61.6 in April from the previous month's level of 61.7. Spain's industrial production surged 12.4% year-over-year in March, while retail sales in Italy declined 0.1% in March. French industrial production increased 0.8% in March, while trade gap increased to EUR 6.1 billion in March from a revised EUR 5.1 billion in February.

Germany reported a current account surplus of EUR 30.2 billion in March versus a EUR 24.8 billion surplus in the year-ago month, while industrial production climbed 2.5% in March.


Economics


The nonfarm payroll number came in at +266,000, well worse than consensus economist expectations of +1 million. The unemployment rate increased by 0.1% to 6.1%.


US wholesale inventories rose 1.3% to $693.6 billion in March.


The Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.


Data on consumer credit for March will be released at 3:00 p.m. ET.

Check out the full economic calendar here

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!